Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29989986 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL1709129 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL30074491 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL5323666 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL29792137 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL7423331 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL29350883 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL22069879 | 0.96 | PTPN1 (0.49) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL20732318 | 0.96 | PTPN1 (0.49) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL31133584 | 0.96 | PTPN1 (0.49) | KMT2AMDM4TP53PTPN1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025118255-A1 | RADIOLABELED FAPI COMPLEX, PREPARATION METHOD THEREFOR, AND USE THEREOF | 北京师范大学 | 2025-06-12 | — | — | WO | claimed |
| CN-116606348-A | Self-assembled supermolecule nano material responding to AXL kinase and preparation method and application thereof | 东南大学 | 2023-08-18 | — | — | CN | claimed |
| CN-114948860-B | Supermolecule hydrogel nano material, gel factor, preparation method and application thereof | 东南大学 | 2023-04-28 | — | — | CN | claimed |
| CN-114948860-A | Supermolecule hydrogel nano material, gelator, preparation method and application thereof | 东南大学 | 2022-08-30 | — | — | CN | claimed |
| US-20250367332-A1 | PSMA-TARGETED RADIOACTIVE METAL COMPLEX CONTAINING NITROAROMATIC HETEROCYCLIC GROUP AND PREPARATION METHOD | UNIV BEIJING NORMAL (CN) | 2025-12-04 | — | — | US | disclosed |
| CN-120202211-A | Cyclic compounds having selective KRAS inhibition over HRAS and NRAS | 中外制药株式会社 | 2025-06-24 | — | — | CN | disclosed |
| WO-2025128626-A1 | HYBRID PEPTIDE COMPOUNDS HAVING A MODIFIED LYSINE RESIDUE | CARMOT THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025128624-A2 | HYBRID PEPTIDE COMPOUNDS HAVING A SUBSTITUTED TRYPTOPHAN RESIDUE OR A TERMINAL SUBSTITUENT | CARMOT THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025118255-A1 | RADIOLABELED FAPI COMPLEX, PREPARATION METHOD THEREFOR, AND USE THEREOF | 北京师范大学 | 2025-06-12 | — | — | WO | disclosed |
| CN-119731195-A | Cyclic compounds having selective inhibition of KRAS over HRAS and NRAS | 中外制药株式会社 | 2025-03-28 | — | — | CN | disclosed |
| EP-4419540-A1 | IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-118359699-A | Therapeutic derivatives of interleukin-22 | 赛托奇制药私人有限公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-4103236-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | Elucida Oncology, Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-108473550-B | EGF (A) analogues with fatty acid substituents | 诺和诺德股份有限公司 | 2022-11-22 | — | — | CN | disclosed |
| EP-4071163-A1 | NUCLEIC ACID COMPLEX AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Eisai R&D Management Co., Ltd (JP) | 2022-10-12 | — | — | EP | disclosed |
| CN-108136043-B | Protein conjugates | 诺和诺德股份有限公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-114948860-A | Supermolecule hydrogel nano material, gelator, preparation method and application thereof | 东南大学 | 2022-08-30 | — | — | CN | disclosed |
| CN-114761422-A | Therapeutic derivatives of interleukin-22 | 赛托奇制药私人有限公司 | 2022-07-15 | — | — | CN | disclosed |
| WO-2022093800-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093793-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367332-A1 | PSMA-TARGETED RADIOACTIVE METAL COMPLEX CONTAINING NITROAROMATIC HETEROCYCLIC GROUP AND PREPARATION METHOD | PSMA1, PSMA2, PSMA7 | KMT2A 768/4885MDM4 877/4885TP53 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.